After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We received an updated WNV package insert; please note the manufacturer and license number has been ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...